🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Colon Carcinoma

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC NCT06553885Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Enfortumab Vedotin Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1 NCT06917963NA2 sites📍 Gdansk📍 Gdynia Medical University of Gdansk · Tests: Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM), S… The Ohio State University (OSU) SCREEN Community Program NCT06666192NA1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers NCT06568016NA2 sites📍 Los Angeles📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Best Practice, Communication Intervention, Communication Intervention, Coordination, Educational Intervention Obstructive Colon Cancer, a Bridge to Surgery in Right Sided Obstructive Colon Cancer NCT06338332n/a1 site📍 Breda Amphia Hospital NIMA-Colon Cancer Study NCT07534852NA1 site📍 Málaga Fundación Pública Andaluza para la Investigación de Málaga … · Tests: Standard hypercaloric-hyperproteic nutritional supplementation, HMB-enriched hypercaloric-hyperproteic nutritional supp… 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 NCT07595874Phase 211 sites📍 Goodyear📍 Corona📍 Duarte City of Hope Medical Center · Tests: Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Magnetic Resonance Imaging Laparoscopic Versus Open Right Colectomy for Right Colon Cancer NCT05713903NA1 site📍 Larissa Larissa University Hospital · Tests: Laparoscopic right colectomy, Open right colectomy A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893NA2 sites📍 San Francisco📍 Walnut Creek University of California, San Francisco · Tests: Radiation Therapy (RT) A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791Phase 130 sites📍 Newport Beach📍 Stanford📍 Miami Eli Lilly and Company · Tests: LY4337713 Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771Phase 18 sites📍 Hackensack📍 Allentown📍 Germantown Bristol-Myers Squibb · Tests: BMS-986488, Adagrasib, Cetuximab, Nivolumab ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort NCT07808164n/a2 sites📍 Hanoi📍 Ho Chi Minh City Tam Anh Research Institute · Tests: IHC analysis for ENPP1, cGAS, and FAP expression A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413 A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors NCT07145255Phase 1, Phase 27 sites📍 San Francisco📍 Grand Rapids📍 East Brunswick MBrace Therapeutics · Tests: ADC START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases NCT07224724n/a1 site📍 Duarte City of Hope Medical Center · Tests: EXELION Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients NCT07673861NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Marsden360 ctDNA test and GTAB review Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection NCT06698146n/a1 site📍 Chicago Northwestern University Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688Phase 1, Phase 211 sites📍 San Antonio📍 Tyler📍 Spokane TiumBio Co., Ltd. · Tests: TU2218 + KEYTRUDA® (Pembrolizumab) BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy